Nephrogenic systemic fibrosis and gadolinium-enhanced magnetic resonance imaging: does a US Food and Drug Administration alert influence practice patterns in CKD?

Am J Kidney Dis. 2010 Sep;56(3):427-30. doi: 10.1053/j.ajkd.2010.07.001.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Adverse Drug Reaction Reporting Systems*
  • Chronic Disease
  • Contrast Media / adverse effects*
  • Gadolinium / adverse effects*
  • Humans
  • Kidney Diseases* / physiopathology
  • Magnetic Resonance Imaging*
  • Nephrogenic Fibrosing Dermopathy / chemically induced*
  • Practice Patterns, Physicians' / standards*
  • United States
  • United States Food and Drug Administration*

Substances

  • Contrast Media
  • Gadolinium